Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | TPH1 | P17752 | 3/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18249986 | 0.88 | PTPN1 (0.42) | SLC7A5PTPN1PTGS1ITGB3ITGA2B | |
| SCHEMBL4629444 | 0.87 | SLC7A5 (0.56) | SLC7A5PTPN1PTGS1ITGB3ITGA2B | |
| SCHEMBL4581449 | 0.87 | SLC7A5 (0.56) | SLC7A5PTPN1PTGS1ITGB3ITGA2B | |
| SCHEMBL9937712 | 0.87 | SLC7A5 (0.56) | SLC7A5PTPN1PTGS1ITGB3ITGA2B | |
| Leucine SCHEMBL4586599 | 0.87 | ITGB3 (0.56) | SLC7A5PTPN1PTGS1ITGB3ITGA2B | |
| Leucine SCHEMBL1724133 | 0.87 | PTPN1 (0.43) | SLC7A5PTPN1PTGS1ITGB3ITGA2B | |
| SCHEMBL11338509 | 0.87 | ANPEP (0.49) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL7560095 | 0.86 | ITGB3 (0.55) | ITGB3ITGA2BLTA4H | |
| SCHEMBL31742540 | 0.85 | SLC7A5 (0.54) | SLC7A5PTPN1PTGS1ITGB3ITGA2B | |
| SCHEMBL8959601 | 0.85 | SLC7A5 (0.54) | SLC7A5PTPN1PTGS1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108653746-B | Multi-drug-loading-point high-drug-loading-rate ligand drug conjugate | 北京键凯科技股份有限公司 | 2021-04-27 | — | — | CN | claimed |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| CN-108653746-B | Multi-drug-loading-point high-drug-loading-rate ligand drug conjugate | 北京键凯科技股份有限公司 | 2021-04-27 | — | — | CN | disclosed |
| US-20200360530-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | UNIV INDIANA RES & TECH CORP (US) | 2020-11-19 | — | — | US | disclosed |
| EP-2970511-B1 | INSULIN-INCRETIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10696726-B2 | Insulin-incretin conjugates | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3206710-B1 | INCRETIN-INSULIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| CN-110959039-A | Novel CAS13B ortholog CRISPR enzymes and systems | 博德研究所 | 2020-04-03 | — | — | CN | disclosed |
| CN-105324397-B | Insulin-incretin conjugates | 印第安纳大学研究及科技有限公司 | 2020-01-14 | — | — | CN | disclosed |
| CN-110560015-A | nano hydrated oxidized metal composite hydrogel and application of nano hydrated oxidized metal composite hydrogel in sewage treatment | 魏旭榕 | 2019-12-13 | — | — | CN | disclosed |
| CN-102307584-A | YL-based insulin-like growth factors exhibiting high activity at the insulin receptor | UNIV INDIANA RES & TECH CORP | 2012-01-04 | — | — | CN | disclosed |
| WO-2011163460-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011159882-A2 | NOVEL STABILIZED INSULIN AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159895-A2 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2376099-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | Indiana University Research & Technology Corporation (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110245164-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010080607-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100120670-A1 | CYCLISED ALPHA-CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-05-13 | — | — | US | disclosed |
| EP-2015766-A1 | CYCLISED ALPHA-CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007118270-A1 | CYCLISED ALPHA-CONOTOXIN PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | SLC7A5 2004/4885PTPN1 1313/4885PTGS1 4814/4885 |
| US-20100120670-A1 | CYCLISED ALPHA-CONOTOXIN PEPTIDES | VIP, CHRNG, CHRND | SLC7A5 1096/4885PTPN1 3350/4885PTGS1 3953/4885 |
| US-10696726-B2 | Insulin-incretin conjugates | GLP1R, IAPP, GIPR | SLC7A5 1933/4885PTPN1 1230/4885PTGS1 4694/4885 |
| US-20110245164-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, INSR, IGFBP1 | SLC7A5 472/4885PTPN1 555/4885PTGS1 3892/4885 |
| US-20200360530-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | FGF23, FGFR1, FGFR3 | SLC7A5 2004/4885PTPN1 1313/4885PTGS1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.